Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Impact of Eptinezumab Treatment on Migraine Frequency, Duration, and Severity in Patients with Migraine
Headache
P2 - Poster Session 2 (8:00 AM-9:00 AM)
7-010
To quantify the amount of time gained back after treatment with eptinezumab in patients with migraine.
Disruption due to migraine can be mitigated by several factors including reducing the number, shortening duration, and lessening severity of migraine, all resulting in time gained back to patients. Eptinezumab, a CGRP monoclonal antibody administered intravenously, has demonstrated migraine preventive efficacy in patients with episodic migraine (EM) and chronic migraine (CM).
PROMISE-1 (NCT02559895) and PROMISE-2 (NCT02974153) were double-blind, randomized, placebo-controlled trials evaluating eptinezumab for migraine prevention (PROMISE-1: 888 patients with EM, four 12-week dosing intervals; PROMISE-2: 1072 patients with CM, two 12-week dosing intervals). Post hoc analyses calculated the expected number of migraine days over a year (baseline rate carried forward for 365 days) vs the number observed (normalized to a 365-day year). A daily eDiary captured duration and severity of migraine as secondary endpoints. 
In PROMISE-1, the expected number of migraine days over 1 year was 113 (100mg), 113 (300mg), and 109 (placebo). The observed number of migraine days was 55, 49, and 62, resulting in gains of 58 and 64 days with eptinezumab vs 47 days with placebo. In PROMISE-2, the expected number of migraine days was 210 (100mg), 210 (300mg), and 212 (placebo). The observed number was 105, 97, and 132, resulting in gains of 105 and 113 days with eptinezumab vs 79 days with placebo. In addition, in both PROMISE-1 and PROMISE-2, treatment with eptinezumab resulted in greater decreases in the median duration of migraine and number of severe migraines vs placebo.
Treatment with eptinezumab resulted in more days without migraine, shorter duration of migraine, and decreased migraine severity versus placebo. Over 6 months, patients with EM and CM can expect to gain back ~1 and ~2 months of migraine-free days, respectively.
Authors/Disclosures
Paul Winner, DO, FÂ鶹´«Ã½Ó³»­ (Palm Beach Headache Ctr)
PRESENTER 		Dr. Winner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. Dr. Winner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan. Dr. Winner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck . Dr. Winner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. Dr. Winner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan. Dr. Winner has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Lundbeck. Dr. Winner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Teva. Dr. Winner has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for lilly. The institution of Dr. Winner has received research support from Amgen. The institution of Dr. Winner has received research support from Allergan. The institution of Dr. Winner has received research support from Lundbeck . The institution of Dr. Winner has received research support from Novartis. The institution of Dr. Winner has received research support from Lilly. The institution of Dr. Winner has received research support from Teva. The institution of Dr. Winner has received research support from Supernus. The institution of Dr. Winner has received research support from Biogen. The institution of Dr. Winner has received research support from Avinar. The institution of Dr. Winner has received research support from SAMUS.
Peter Goadsby, MD, PhD, FRS (King Abdullah Univeristy of Science and Technology) Dr. Goadsby has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva Pharmaceuticals. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Goadsby has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CoolTech LLC. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PureTech Health LLC. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Kallyope. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Seaport Therapeutics. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dr Reddy's. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Orion Pharma. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ipsen. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Massachusetts Medical Society. The institution of Dr. Goadsby has received research support from NIHR. Dr. Goadsby has received publishing royalties from a publication relating to health care. Dr. Goadsby has received publishing royalties from a publication relating to health care. Dr. Goadsby has a non-compensated relationship as a Trustee with Migraine Trust that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Goadsby has a non-compensated relationship as a Trustee with Organisation for Understanding Cluster Headache (UK) that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Abigail L. Chua, DO (Geisinger Wyoming Valley Health Center, Neurology) Dr. Chua has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clinical Â鶹´«Ã½Ó³»­ Alliance.
Deborah I. Friedman, MD, MPH, FÂ鶹´«Ã½Ó³»­ Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Friedman has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Pfizer. Dr. Friedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Friedman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie. Dr. Friedman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Axsone. Dr. Friedman has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Pfizer. Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MedLink Neurology . Dr. Friedman has a non-compensated relationship as a Program Co-Chair, Scottsdale Headache Symposium with American Headache Society that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Friedman has a non-compensated relationship as a Medical Advisor with Spinal CSF Leak Foundation that is relevant to Â鶹´«Ã½Ó³»­ interests or activities. Dr. Friedman has a non-compensated relationship as a President-elect, Board of Directors with Southern Headache Society that is relevant to Â鶹´«Ã½Ó³»­ interests or activities.
Yufan Zhao No disclosure on file
Roger Cady, MD (RK Consulting, LLC) Dr. Cady has received personal compensation for serving as an employee of Lundbeck. Dr. Cady has stock in Alder Biopharmaceutical.